Skip to main content

Table 1 Baseline characteristics of the 251 patients with N0-category nasopharyngeal carcinoma (NPC) and enlarged neck lymph nodes (ENLNs)

From: Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

Characteristic

Total (cases)

Small ENLN group [cases (%)]

Large ENLN group [cases (%)]

P valuea

Gender

   

0.923

 Male

194

66 (77.6)

128 (77.1)

 

 Female

57

19 (22.4)

38 (22.9)

 

Age (years)

   

0.661

 <50

167

55 (64.7)

112 (67.5)

 

 ≥50

84

30 (35.3)

54 (32.5)

 

Smoking

   

0.935

 Yes

73

25 (29.4)

48 (28.9)

 

 No

178

60 (70.6)

118 (71.1)

 

Drinking

   

0.836

 Yes

25

8 (9.4)

17 (10.2)

 

 No

226

77 (90.6)

149 (89.8)

 

LDH (U/L)

   

0.973

 <245

242

82 (96.5)

160 (96.4)

 

 ≥245

9

3 (3.5)

6 (3.6)

 

Family history of cancer

   

0.332

 Yes

87

26 (30.6)

61 (36.7)

 

 No

164

59 (69.4)

105 (63.2)

 

BED (Gy)

   

0.821

 <72

91

30 (35.3)

61 (36.7)

 

 ≥72

160

55 (64.7)

105 (63.3)

 

Chemotherapy

   

0.222

 Yes

152

47 (55.3)

105 (63.3)

 

 No

99

38 (44.7)

61 (36.7)

 

T categoryb

   

0.270

 T1

80

27 (31.8)

53 (31.9)

 

 T2

54

24 (28.2)

30 (18.1)

 

 T3

87

25 (29.4)

62 (37.3)

 

 T4

30

9 (10.6)

21 (12.7)

 
  1. The patients were divided into small and large ENLN groups using the cut-off value (5.5 mm) of the short diameter of the largest ENLN for the prediction of DFS
  2. LDH lactate dehydrogenase, BED biological equivalent dose
  3. a P values were calculated using the Chi square test or Fisher’s exact test if indicated
  4. bAccording to the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system